Education
About Us
Working with TipRanks
Follow Us
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
Total Valuation
ACADIA Pharmaceuticals has a market cap or net worth of $3.75B. The enterprise value is $3.62B.
Market Cap$3.75B
Enterprise Value$3.62B
Share Statistics
ACADIA Pharmaceuticals has 170,494,610 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding170,494,610
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
ACADIA Pharmaceuticals’s return on equity (ROE) is 0.32 and return on invested capital (ROIC) is 8.07%.
Return on Equity (ROE)0.32
Return on Assets (ROA)0.25
Return on Invested Capital (ROIC)8.07%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee1.64M
Profits Per Employee598.77K
Employee Count653
Asset Turnover0.69
Inventory Turnover2.57
Valuation Ratios
The current PE Ratio of ACADIA Pharmaceuticals is 11.6. ACADIA Pharmaceuticals’s PEG ratio is 0.17.
PE Ratio11.6
PS Ratio4.22
PB Ratio3.69
Price to Fair Value3.69
Price to FCF43.02
Price to Operating Cash Flow33.87
PEG Ratio0.17
Income Statement
In the last 12 months, ACADIA Pharmaceuticals had revenue of 1.07B and earned 391.00M in profits. Earnings per share was 2.32.
Revenue1.07B
Gross Profit982.51M
Operating Income104.81M
Pretax Income138.90M
Net Income391.00M
EBITDA138.90M
Earnings Per Share (EPS)2.32
Cash Flow
In the last 12 months, operating cash flow was 109.84M and capital expenditures -4.69M, giving a free cash flow of 105.15M billion.
Operating Cash Flow109.84M
Free Cash Flow105.15M
Free Cash Flow per Share0.62
Dividends & Yields
ACADIA Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.13
52-Week Price Change30.93%
50-Day Moving Average24.86
200-Day Moving Average23.79
Relative Strength Index (RSI)38.03
Average Volume (3m)1.68M
Important Dates
ACADIA Pharmaceuticals upcoming earnings date is May 13, 2026, After Close (Confirmed).
Last Earnings DateFeb 25, 2026
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
ACADIA Pharmaceuticals as a current ratio of 3.83, with Debt / Equity ratio of 4.25%
Current Ratio3.83
Quick Ratio3.71
Debt to Market Cap<0.01
Net Debt to EBITDA-0.90
Interest Coverage Ratio0.00
Taxes
In the past 12 months, ACADIA Pharmaceuticals has paid -252.10M in taxes.
Income Tax-252.10M
Effective Tax Rate-1.81
Enterprise Valuation
ACADIA Pharmaceuticals EV to EBITDA ratio is 31.66, with an EV/FCF ratio of 41.82.
EV to Sales4.10
EV to EBITDA31.66
EV to Free Cash Flow41.82
EV to Operating Cash Flow40.04
Balance Sheet
ACADIA Pharmaceuticals has $819.69M in cash and marketable securities with $52.19M in debt, giving a net cash position of $767.50M billion.
Cash & Marketable Securities$819.69M
Total Debt$52.19M
Net Cash$767.50M
Net Cash Per Share$4.50
Tangible Book Value Per Share$6.61
Margins
Gross margin is 91.69%, with operating margin of 9.78%, and net profit margin of 36.49%.
Gross Margin91.69%
Operating Margin9.78%
Pretax Margin12.96%
Net Profit Margin36.49%
EBITDA Margin12.96%
EBIT Margin12.96%
Analyst Forecast
The average price target for ACADIA Pharmaceuticals is $32.53, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$32.53
Price Target Upside48.07% Upside
Analyst ConsensusModerate Buy
Analyst Count16
Revenue Growth Forecast12.69%
EPS Growth Forecast100.80%